Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer

• US 10,640,493 B2
• Filed: 07/30/2019
• Issued: 05/05/2020
• Est. Priority Date: 06/24/2016
• Status: Active Grant

• Current Assignee: AtlasMedx, Inc., Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Peto, Csaba J., Jablons, David M., Tsang, Tsze, Lemjabbar-Alaoui, Hassan
• Primary Examiner(s): Ward, Paul V
• Application Number:
  US16/526,620
• Publication Number:
  US 20190352283A1
• Time in Patent Office: Days
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 403/10 linked by a carbon chain containing aromatic rings
• CPC Class Codes: C07D 403/14 containing three or more hetero rings
• CPC Class Codes: C07D 405/14 containing three or more hetero rings
• CPC Class Codes: C07D 407/14 containing three or more hetero rings
• CPC Class Codes: C07D 413/14 containing three or more hetero rings
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

This invention provides, among other things, compounds useful for treating diseases such as cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.

Claims

1. A compound, or a pharmaceutically acceptable salt thereof, having a structure which is

2. A hydrochloric salt of a compound having a structure which is

3. A pharmaceutical formulation comprising:

a) a compound, or a pharmaceutically acceptable salt thereof, having a structure which is

4. A pharmaceutical formulation comprising:

a) a hydrochloric salt of a compound having a structure which is